Chronic Obstructive Pulmonary Disease
Infliximab treatment study of patients with pulmonary disease is inconclusive
Published in Respiratory Therapeutics Week, October 3rd, 2005
According to a study from Netherlands, "Tumor necrosis factor-alpha is believed to be important in the induction and maintenance of airway inflammation in chronic obstructive pulmonary disease. We aimed to evaluate the effect of the anti-tumor necrosis factor-a drug infliximab in patients with chronic obstructive pulmonary disease, with percentage of sputum neutrophils as the primary endpoint."
"We performed an exploratory single-center, double-blind, placebo-controlled, randomized, phase 2 trial in which 22 current smokers with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
More Articles from Respiratory Therapeutics Week
- Chronic Obstructive Pulmonary Disease
COPD bronchoalveolar lavage fluid studied, effect of smoking revealed - Lung Cancer
Polymorphisms in DNA nucleotide excision repair genes linked to lung cancer risk - Lung Cancer
Radiation therapy potentiated effective oncolytic viral therapy - Respiratory Medicine
Multi-, binucleate cells may be biomarkers of inflammation in the lungs - Trends
Update published on U.S. death rate and leading causes of death over 30 years - Apoptosis
Studies add new findings to apoptosis body of knowledge - More from this issue of Respiratory Therapeutics Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
